SEC Contract Filing

Filing Date: 2017-08-11

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>reph-ex101_328.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
reph-ex101_328.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Exhibit 10.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Execution Version</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:16pt;font-family:Times New Roman Bold;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Third Amendment to Development, Manufacturing and Supply Agreement</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_cp_text_1_4"></a>This Third Amendment to Development, Manufacturing and Supply Agreement<font style="font-weight:normal;font-variant: normal;"> (this &#8220;</font><font style="font-variant: normal;">Third</font><font style="font-weight:normal;font-variant: normal;"> </font><font style="font-variant: normal;">Amendment</font><font style="font-weight:normal;font-variant: normal;"><a name="_cp_text_1_4"></a>&#8221;) is made and entered into as of June 15, 2017 by and between Alkermes Pharma Ireland Limited, a private limited company organized and existing under the laws of the Republic of Ireland (&#8220;</font><font style="font-variant: normal;">Alkermes</font><font style="font-weight:normal;font-variant: normal;">&#8221;), and Recro Ireland Limited, a private limited company organized and existing under the laws of the Republic of Ireland (&#8220;</font><font style="font-variant: normal;">Recro</font><font style="font-weight:normal;font-variant: normal;">&#8221;).&nbsp;&nbsp;Recro and Alkermes are sometimes hereinafter referred to each as a &#8220;</font><font style="font-variant: normal;">Party</font><font style="font-weight:normal;font-variant: normal;">&#8221; and collectively as the &#8220;</font><font style="font-variant: normal;">Parties</font><font style="font-weight:normal;font-variant: normal;">.&#8221;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;">Recitals:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Alkermes and Recro Pharma, Inc. entered into that certain Development, Manufacturing and Supply Agreement on July 10, 2015, as amended by that certain First Amendment to the Development, Manufacturing and Supply Agreement between Alkermes and Recro Pharma, Inc. dated as of October 19, 2016 and by that certain Second Amendment to the Development, Manufacturing and Supply Agreement between Alkermes and Recro Pharma, Inc. dated as of February 1, 2017 (the &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;);</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, with effect from March 7, 2017, the Agreement was assigned by Recro Pharma, Inc. to Recro;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties desire to amend the terms of the Agreement as set forth herein to provide for certain requests by Recro, the procedure governing the calculation and payment of the amounts payable by Recro to Alkermes for all Services performed with respect to the Requirements under Section 7.1(c) of the Agreement and other miscellaneous matters.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;">Agreement:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Now, therefore,<font style="font-weight:normal;font-variant: normal;"> for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Alkermes and Recro agree as follows:</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#010000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref1978805"></a>Article 1<font style="color:#000000;"><br /><a name="_Ref1978805"></a>Definitions</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-align:justify;text-indent:7.69%;color:#010000;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-varia